As the first and only FDA-approved treatment for low-grade upper tract urothelial #cancer, JELMYTO is changing the treatment paradigm with an innovative, kidney-sparing approach. Please see Important Safety Information and learn more: bit.ly/3gvnmfl

A new study examines the administration of JELMYTO via nephrostomy tube. Learn more and see Important Safety Information: bit.ly/3BiJrGX For important information about nephrostomy tube administration of JELMYTO, click here: jelmyto.com/pdf/jelmyto-ne…

Discover how JELMYTO® (mitomycin) for pyelocalyceal solution is pushing perspectives and redefining possibilities. Find us at #AUA23 to see for yourself! bit.ly/AUA_Pre4 #Urology #Sponsored

Fresh coffee and fresh perspectives – visit us at the UroGen Pharma Booth #1338 at #AUA23. Can’t join us in Chicago? Visit our website for more JELMYTO information and resources.

Get fresh coffee and a fresh perspective on @JELMYTO at the UroGen Pharma booth! bit.ly/AUA_Conf3 #Urology #UroOncology #Sponsored #AUA23

Are you ready to redefine possibilities in your practice? Visit the UroGen Pharma Booth #1338 to connect with our team and learn more about JELMYTO.

Are you ready to redefine possibilities at #AUA23? See things from a new angle at the UroGen Pharma booth. bit.ly/AUA_Conf5 #Urology #Sponsored @JELMYTO

Did you get a different perspective on JELMYTO® (mitomycin) for pyelocalyceal solution at #AUA23? If you didn't get a chance, you can still redefine possibilities by exploring the recently updated website: bit.ly/AUA_Post2 #Urology #Sponsored

Jennifer Linehan, MD and Dr Sandip M Prasad had a spirited discussion about @JELMYTO at UroGen Pharma’s Product Theater at #AUA23. In case you missed it, you can still get a different perspective at bit.ly/AUA_Post3 #Urology #UroOncology #Sponsored

Kathy, living with low-grade upper tract urothelial cancer (LG-UTUC), endured multiple recurrences and some complications from endoscopic procedures. Click here to learn about Kathy’s experience when she began treatment with JELMYTO as well as view the full PI.

We are celebrating the fourth anniversary of the FDA approval of JELMYTO® and its impact on the lives of adults living with low-grade upper tract urothelial cancer (LG-UTUC). For Important Safety and Product Information, see the video below and visit bit.ly/43h8iJ3

Hello, San Antonio! Our team is looking forward to meeting #AUA24 attendees at Booth #1525. Stop by and hear the latest from the JELMYTO® (mitomycin) team!

#AUA24 attendees: in need of some fuel to get your day started? Visit us at Booth #1525 for a cup of coffee. We look forward to meeting you! ☕

Jennifer Kirsch, Regional Business Director, shares partner feedback on the impact of JELMYTO® (mitomycin) for pyelocalyceal solution on adults with low-grade upper tract urothelial cancer (LG-UTUC). For Important Safety and Product Information: bit.ly/43h8iJ3 #UTUC

Terry Wolfsheimer, Senior Territory Business Manager, has been with UroGen since the launch of JELMYTO® (mitomycin) for pyelocalyceal solution and shares his excitement for the future. For Important Safety and Product Information, visit bit.ly/43h8iJ3 #UTUC